- Home
- INMB vs ALGS Comparison
INMB vs ALGS Comparison
Compare INMB & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ALGS
- Stock Information
- Founded
- INMB 2015
- ALGS 2018
- Country
- INMB United States
- ALGS United States
- Employees
- INMB N/A
- ALGS N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- ALGS Health Care
- Exchange
- INMB Nasdaq
- ALGS Nasdaq
- Market Cap
- INMB 112.0M
- ALGS 118.8M
- IPO Year
- INMB 2019
- ALGS 2020
- Fundamental
- Price
- INMB $4.40
- ALGS $39.84
- Analyst Decision
- INMB Strong Buy
- ALGS Strong Buy
- Analyst Count
- INMB 2
- ALGS 1
- Target Price
- INMB $21.00
- ALGS $75.00
- AVG Volume (30 Days)
- INMB 215.6K
- ALGS 428.8K
- Earning Date
- INMB 10-31-2024
- ALGS 11-06-2024
- Dividend Yield
- INMB N/A
- ALGS N/A
- EPS Growth
- INMB N/A
- ALGS N/A
- EPS
- INMB N/A
- ALGS N/A
- Revenue
- INMB $42,000.00
- ALGS $5,997,000.00
- Revenue This Year
- INMB N/A
- ALGS N/A
- Revenue Next Year
- INMB N/A
- ALGS N/A
- P/E Ratio
- INMB N/A
- ALGS N/A
- Revenue Growth
- INMB N/A
- ALGS N/A
- 52 Week Low
- INMB $4.32
- ALGS $6.76
- 52 Week High
- INMB $14.74
- ALGS $41.64
- Technical
- Relative Strength Index (RSI)
- INMB 37.57
- ALGS 80.76
- Support Level
- INMB $4.74
- ALGS $28.00
- Resistance Level
- INMB $5.16
- ALGS $35.89
- Average True Range (ATR)
- INMB 0.38
- ALGS 4.05
- MACD
- INMB -0.05
- ALGS 0.51
- Stochastic Oscillator
- INMB 5.56
- ALGS 89.77
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.